잠시만 기다려 주세요. 로딩중입니다.

Fibrostenotic strictures in Crohn’s disease

Intestinal Research 2020년 18권 4호 p.379 ~ 401
유준환, Holubar Stefan, Rieder Florian,
소속 상세정보
유준환 ( Yoo Jun-Hwan ) - CHA University School of Medicine CHA Bundang Medical Center Digestive Disease Center
 ( Holubar Stefan ) - Cleveland Clinic Foundation Digestive Diseases and Surgery Institute Department of Colorectal Surgery, Hepatology and Nutrition
 ( Rieder Florian ) - Cleveland Clinic Foundation Digestive Diseases and Surgery Institute Department of Gastroenterology, Hepatology and Nutrition

Abstract


The use of biologic agents including anti-tumor necrosis factor monoclonal antibodies followed by anti-integrins and anti-interleukins has drastically changed the treatment paradigm of Crohn’s disease (CD) by improving clinical symptoms and mucosal healing. However, up to 70% of CD patients still eventually undergo surgery mainly due to fibrostenotic strictures. There are no specific anti-fibrotic drugs yet. This review comprehensively addresses the mechanism, prediction, diagnosis and treatment of the fibrostenotic strictures in CD. We also introduce promising anti-fibrotic agents which may be available in the near future and summarize challenges in developing novel therapies to treat fibrostenotic strictures in CD.

키워드

Crohn disease; Stricture; Fibrostenosis; Intestinal fibrosis; Endoscopic balloon dilatation

원문 및 링크아웃 정보

 

등재저널 정보

KCI
KoreaMed
KAMS